Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$54.26 - $173.25
Previous CloseN/A
Volume185.86K
Average Volume (3M)2.34M
Market Cap
$5.28B
Enterprise Value$13.18B
Total Cash (Recent Filing)$557.23M
Total Debt (Recent Filing)$430.81M
Price to Earnings (P/E)22.8
Beta1.06
Next Earnings
Apr 30, 2025EPS Estimate
-2.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.38
Shares Outstanding97,032,074
10 Day Avg. Volume2,724,161
30 Day Avg. Volume2,337,668
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.78
Price to Cash Flow (P/CF)19.50
P/FCF Ratio21.30
Enterprise Value/Market Cap2.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.32
Enterprise Value/Ebitda43.10
Forecast
1Y Price Target
$159.76Price Target Upside193.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Commercial OpportunityThe risk/benefit profile of Elevidys remains favorable representing an attractive commercial opportunity.
Company ExpertiseSarepta is uniquely positioned to leverage its DMD expertise, broad patient/payer/prescriber access, and market leadership to drive Elevidys revenue growth.
Market ValuationShares are viewed as grossly undervalued, especially when considering the sales that will be generated in future.
Bears Say
Clinical TrialsThe clinical hold on key ELEVIDYS trials in Europe is seen as heightening the uncertainty around the future of the franchise.
Patient SafetySuch severe side effects associated with mortality can certainly be alarming and cause the community to question the risk/benefit of treating older patients.
Regulatory ImpactThe news about the clinical hold is anticipated to discourage use in US markets, especially in non-ambulatory patients.
---
Ownership Overview
4.14% Insiders
30.64% Mutual Funds
32.38% Other Institutional Investors
12.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $54.26 and its highest was $173.25 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $5.28B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Apr 30, 2025 which is in 23 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Feb 26, 2025. The company reported $1.5 earnings per share for the quarter, missing the consensus estimate of $1.883 by -$0.383.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -2.83.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 97,032,074 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $1.5 in its last earnings report, missing expectations of $1.883. Following the earnings report the stock price went down -3.556%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
---
Sarepta Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$159.76 (193.51% Upside)
$159.76 (193.51% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 93%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 357.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $248.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.72%
12-Months-Change
Fundamentals
Return on Equity
19.71%
Trailing 12-Months
Asset Growth
21.40%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics (SRPT) is a biopharmaceutical company specializing in the development of precision genetic medicines to treat rare neuromuscular diseases. With a focus on Duchenne muscular dystrophy (DMD), Sarepta leverages its expertise in RNA-targeted therapies, gene therapy, and gene editing to develop innovative treatments that address the underlying genetic causes of these conditions. The company's core products include Exondys 51, Vyondys 53, and Amondys 45, which are exon-skipping therapies designed to treat specific mutations in the DMD gene.
---
SRPT Company Deck
---
SRPT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects a highly positive performance with record-breaking revenue growth, successful ELEVIDYS launch, and strong guidance for 2025. Although there are challenges related to insurance and manufacturing, the overall outlook remains robust due to strategic advancements and pipeline progress.Read More>---
SRPT Stock 12 Month Forecast
Average Price Target
$159.76
▲(193.51% Upside)
Technical Analysis
Alkermes
―
Blueprint Medicines
―
Axsome Therapeutics
―
Revolution Medicines
―
Legend Biotech
―
Best Analysts Covering SRPT
1 Year
1 Year Success Rate
29/45 ratings generated profit
1 Year Average Return
+10.59%
reiterated a buy rating 5 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 64.44% of your transactions generating a profit, with an average return of +10.59% per trade.
---